spacer
home > > autumn 2003 > establishing the patient recruitment algorithm - should we apply a more heuristic approach?
PUBLICATIONS


Establishing the Patient Recruitment Algorithm - Should we Apply a more Heuristic Approach?

The continuing series of articles offering advice on how to improve the recruitment of patients into clinical trials confirms that patient recruitment remains one of the key challenges faced by the pharmaceutical industry. A critical and objective look at the topic might provide us with some clues as to why this should be so. Is it just a case of throwing solutions (and money) at the problem, or do we need to change the way we look at the whole issue?

Patient Recruitment and Retention in the Project Planning Stage

Clinical drug development seems to be all about numbers. Typically, a trial may begin with a proposition:

“Our new drug should show a 10 per cent improvement in efficacy compared to the gold standard and to demonstrate this, we must enrol 720 patients into our Phase III trial and produce evaluable data on 600 of them. Drug development timelines dictate that we complete enrolment within 12 months”.

An optimum number of investigator sites, let’s say 30, from which all the patients must be recruited will be determined so that by the time the study goals are filtered down to each Clinical Research Associate (CRA), he or she will be targeted with enrolling 24 patients in each of his sites within a 12 month period. Instinctively, the CRA sets himself an average enrolment target of two patients per site per month and plots a linear graph of planned recruitment over time (Figure 1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tom Ruane, Director of Patient Recruitment & Retention at Quintiles

Tom Ruane has over 14 years' experience in international clinical development activities. Having enjoyed a variety of roles with various pharmaceutical companies and CROs, as well as the National Health Service, he is now Director of the patient recruitment and retention team at Quintiles.

The team maintains a strong focus on identifying potential patient populations, while devising and executing appropriate recruitment and retention strategies for clinical trials. Tom regularly presents at international meetings on the subject of clinical trial patient recruitment.

spacer
Tom Ruane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement